| |
Thursday, February 20, 2025 | 2pm ET / 11am PT Clinical trials only continue to increase in complexity. Join industry experts to explore how AI can transform workflows to help sponsors and CROs better manage data while maintaining speed, quality and compliance. Register now. 
|
|
Today’s Big NewsJan 27, 2025 |
|
Wednesday, February 12, 2025 | 10am ET / 7am PT If you are a company developing advanced therapies, don’t miss this webinar to learn about packaging innovations and aseptic filling solutions that meet the demands of emerging therapies and ensure product integrity, safety and efficiency. Register now. 
|
|
| By Nick Paul Taylor Akero Therapeutics has hit a home run, reporting statistically significant results in two key 96-week metabolic dysfunction-associated steatohepatitis analyses to send its stock up about 100%. |
|
|
|
By James Waldron Metsera has set its sights on a hefty $289 million IPO as the next-gen obesity biotech seeks to fund a phase 3 trial of its GLP-1 receptor agonist. |
By James Waldron Maze Therapeutics has set out plans for a $131 million IPO as the company prepares to take its lead kidney drug through a phase 2 trial. |
By Gabrielle Masson The FDA’s guidance detailing diversity action plans for clinical trials that evaluate drugs, devices and other medical products has been taken down from the agency’s website. |
|
Thursday, February 20, 2025 | 1pm ET / 10am PT ALS remains one of the most complex neurological diseases to understand and treat. Join industry experts to learn about the latest advancements in ALS research, with exclusive insights into the latest scientific progress shaping the future of ALS therapies. Register now. 
|
|
By Nick Paul Taylor Allakos is throwing in the towel. After seeing phase 1 data in hives, the biotech has decided to drop the drug candidate and lay off 75% of its employees to hunker down while exploring strategic alternatives. |
By James Waldron The study hit its primary endpoint of showing a statistically significant preservation of total lean body mass at 16 weeks in patients receiving enobosarm compared to those who received placebo. |
By Andrea Park,Nick Paul Taylor According to Evaluate’s forecasts, the biggest potential drug launches of the coming year stand to generate a collective $29 billion in annual sales by the end of the decade, nearly double the estimate for last year’s top 10. |
By James Waldron Japan’s Nippon Shinyaku is continuing to scoop up the international rights to some intriguing drugs, this time penning a $650 million biobucks deal for AB2 Bio’s late-stage autoimmune disease therapy. |
By Darren Incorvaia Despite making up a sizable chunk of entry-level employees at the biggest U.S. biopharmas, the share of east Asian Americans drops dramatically as you move up the ranks. That’s according to a report from ElevAAte Biotech, a new nonprofit that seeks to boost the biopharma C-suite representation of Americans who descend from countries like China, Japan, South Korea and Taiwan. |
By Darren Incorvaia British pharma giant GSK is heading back to school, pledging up to 50 million pounds sterling (about $62.4 million) to work with the University of Oxford on cancer vaccines. |
By Angus Liu Old drugs from Bristol Myers Squibb and Pfizer have delivered what the companies and researchers believe could establish them as new standard treatments for certain colorectal cancer patients. |
By Paige Minemyer Change Healthcare now estimates that 190 million people were affected in the massive cyberattack that took down its services nearly a year ago. |
By Andrea Park Not long after reporting phase 2 data for one of its obesity candidates that appeared to put it on par with Eli Lilly’s Zepbound, Kailera Therapeutics is preparing for an eventual market launch with a new commercial leader. |
Fierce podcasts Don’t miss an episode |
| This week on “The Top Line,” we break down the biggest stories out of JPM, from J&J’s blockbuster acquisition of Intra-Cellular Therapies to former First Lady Jill Biden’s appearance at Fierce JPM Week. |
|
|---|
|
|
|
Wednesday, February 19, 2025 | 11am ET / 8am PT This webinar takes a deep dive into effective formulation strategies to overcome current solubility and bioavailability hurdles. Join us to explore the latest advancements in bioavailability enhancement technologies and critical factors for selecting the right formulation approach. Register now. 
|
|
Whitepaper How can an emerging company attract the right partner for a therapeutic asset (& optimize its value in a transaction)? This paper offers some insights. Presented by: Blue Matter, strategic consultants in the life sciences |
| |
|
